Maxim Starts Dendreon (DNDN) at Sell, Sets $5 Price Target
Tweet Send to a Friend
Get Alerts DNDN Hot Sheet
Price: $3.99 --0%
Rating Summary:
5 Buy, 15 Hold, 12 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 2 | New: 2
Rating Summary:
5 Buy, 15 Hold, 12 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 2 | New: 2
Trade DNDN Now!
An analyst at Maxim Group initiated coverage on shares of Dendreon (NASDAQ: DNDN) with a Sell rating and $5 price target Friday morning.
The call to sell shares comes despite a 35 percent decline in Dendreon shares since the company reported better-than-expected Q1 results on the evening of May 7th. The stock tumbled about 25 percent on May 8th, but more downside was seen amid recent concerns related to an open SEC investigation and also worries J&J's Zytiga is superior to Provenge. Dendreon shares fell another 11 percent on Thursday amid these two fears.
With Dendreon shares down 0.65 percent to $7.60 in pre-open action Friday, Maxim's new price target implies further downside of about 34 percent.
For an analyst ratings summary and ratings history on Dendreon click here. For more ratings news on Dendreon click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The call to sell shares comes despite a 35 percent decline in Dendreon shares since the company reported better-than-expected Q1 results on the evening of May 7th. The stock tumbled about 25 percent on May 8th, but more downside was seen amid recent concerns related to an open SEC investigation and also worries J&J's Zytiga is superior to Provenge. Dendreon shares fell another 11 percent on Thursday amid these two fears.
With Dendreon shares down 0.65 percent to $7.60 in pre-open action Friday, Maxim's new price target implies further downside of about 34 percent.
For an analyst ratings summary and ratings history on Dendreon click here. For more ratings news on Dendreon click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Keryx Biopharma (KERX) Patents Strong; JPMorgan Starts at Overweight
- Credit Suisse Starts Coca-Cola (KO) at Outperform
- Goldman Sachs Starts Quintiles (Q) at Neutral
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Maxim GroupLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

